Foreign listings of BioNTech, CureVac & Co. (in German)

The study "Foreign Listings of BioNTech, CureVac & Co. - Recommendations for policymakers for more IPOs in Germany", in cooperation with RITTERSHAUS Rechtsanwälte, answers the question why German high-growth companies go public abroad.

The main reason is an efficient capital market ecosystem, in which the financial strength and expertise of investors in particular play a major role. To firmly establish a capital market ecosystem in Germany as well, we need to mobilize more capital to finance growth companies via an equity-oriented pension scheme. Furthermore, policymakers must make stock corporation law more flexible.